© 2005 Oxford University Press
ARTICLE |
Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
Affiliations of authors: Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Washington, DC (KWH, HAY, PHL); Cancer Prevention Fellowship Program, Division of Cancer Prevention (KWH), Division of Cancer Epidemiology and Genetics (WFA, SSD), National Cancer Institute, National Institutes of Health, Bethesda, MD; The George Washington University Cancer Institute, Washington, DC (PHL)
Correspondence to: Kenneth W. Hance, PhD, MPH, Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, 6120 Executive Blvd., Suite T41, Bethesda, MD 20892 (e-mail: hancek{at}mail.nih.gov).
Background: Inflammatory breast carcinoma (IBC) appears to be a clinicopathologic entity distinct from noninflammatory locally advanced breast cancer (LABC). We examined incidence and survival trends for IBC in Surveillance, Epidemiology, and End Results (SEER) Program data with a case definition designed to capture many of its unique clinical and pathologic characteristics. Methods: We analyzed breast cancer cases diagnosed in the SEER 9 Registries (n = 180 224), between 1988 and 2000. Breast cancer cases were categorized using SEER's "Extent of Disease" codes in combination with International Classification of Diseases for Oncology morphology code 8530/3 and classified as IBC (n = 3648), LABC (n = 3636), and non-T4 breast cancer (n = 172 940). We compared changes in incidence rates over 3-year intervals by breast cancer subtype and race using SEER*Stat. Survival differences by breast cancer subtype and race were assessed using Kaplan–Meier curves and log-rank statistics. All statistical tests were two-sided. Results: Between 1988 and 1990 and 1997 and 1999, IBC incidence rates (per 100 000 woman-years) increased from 2.0 to 2.5 (P<.001), whereas those for LABC declined (2.5 to 2.0, P = .0025), as did those for non-T4 breast cancer (108 to 101, P = .0084). IBC incidence rates were statistically significantly higher in black women (3.1) than in white women (2.2) during the study period (P<.001). Women diagnosed with IBC had statistically significantly poorer survival than women with either LABC or non-T4 breast cancer (log-rank test, P<.001). Median survival of women with IBC (2.9 years) was statistically significantly shorter than that of women with LABC (6.4 years; P<.0001) or non-T4 breast cancer (>10 years, P<.0001). Black women with IBC or LABC had poorer survival than white women with IBC or LABC, respectively (log-rank test, P<.001). Conclusions: Throughout the 1990s, IBC incidence rose, and survival improved modestly. Substantial racial differences were noted in age at diagnosis, age-specific incidence rates, and survival outcomes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. I. Labidi, K. Mrad, A. Mezlini, M. A. Ouarda, J. D. Combes, M. B. Abdallah, K. B. Romdhane, P. Viens, and F. B. Ayed Inflammatory breast cancer in Tunisia in the era of multimodality therapy Ann. Onc., March 1, 2008; 19(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Ancheta, H. Lewin, J. Said, and S. A. Hurvitz Primary Dural Marginal Zone Lymphoma in a Woman With Inflammatory Breast Cancer J. Clin. Oncol., January 10, 2008; 26(2): 326 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Aird, X. Ding, A. Baras, J. Wei, M. A. Morse, T. Clay, H. K. Lyerly, and G. R. Devi Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Mol. Cancer Ther., January 1, 2008; 7(1): 38 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al. Trends for Inflammatory Breast Cancer: Is Survival Improving? Oncologist, August 1, 2007; 12(8): 904 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nguyen, K. Sam, A. Tsimelzon, X. Li, H. Wong, S. Mohsin, G. M. Clark, S. G. Hilsenbeck, R. M. Elledge, D. C. Allred, et al. Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype Clin. Cancer Res., September 1, 2006; 12(17): 5047 - 5054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Smoot, C. A. Koch, A. C. Degnim, S. Sterioff, J. H. Donohue, C. S. Grant, S. A. Barnes, R. E. Gullerud, T. J. Hobday, and D. R. Farley A Single-Center Experience With Inflammatory Breast Cancer, 1985-2003 Arch Surg, June 1, 2006; 141(6): 567 - 573. [Abstract] [Full Text] [PDF]
|
|